John R Lee1, Darshana Dadhania, Phyllis August, Jun B Lee, Manikkam Suthanthiran, Thangamani Muthukumar. 1. 1 Division of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medical College, New York, NY. 2 Department of Transplantation Medicine, New York Presbyterian Hospital - Weill Cornell Medical Center, New York, NY. 3 The Rogosin Institute, New York, NY. 4 Address correspondence to: Thangamani Muthukumar, M.D., Division of Nephrology and Hypertension, Department of Medicine, 525 E 68th St, Box 3, New York, NY 10065.
Abstract
BACKGROUND: Vitamin D, in addition to its established role in bone metabolism, may regulate the immune system and affect the outcome of allografts. METHODS: We identified 351 kidney allograft recipients who had serum levels of 25-hydroxyvitamin D (25[OH]D) measured within the first 30 days of transplantation. We evaluated the relationship between the circulating levels of 25(OH)D and acute cellular rejection (ACR), cytomegalovirus (CMV) disease, BK virus nephropathy, and kidney graft function. RESULTS: Vitamin D deficiency (circulating levels of 25[OH]D ≤20 ng/mL, defined using The Endocrine Society Clinical Practice 2011 Guideline) was observed in 216 (61.5%) of 351 kidney graft recipients. Vitamin D deficiency was more frequent in female recipients (P=0.007, Fisher exact test) and African American recipients (P<0.001) and was less frequent in preemptive kidney graft recipients (P=0.002). Biopsy-confirmed ACR was more frequent in the vitamin D-deficient group than in the sufficient group (10.2% vs. 3.7%, P=0.04). By multivariable Cox regression analysis, vitamin D deficiency was an independent risk factor for ACR (hazard ratio=3.3, P=0.02). Vitamin D deficiency was not associated with CMV disease, BK virus nephropathy, or kidney allograft function at 1 year. 1,25-Dihydroxyvitamin D3 supplementation initiated within the first 90 days of transplantation was associated with a lesser incidence of ACR compared to no treatment with 1,25-dihydroxyvitamin D3 (5.1% vs. 13.0%, P=0.099). CONCLUSIONS: Vitamin D deficiency is an independent risk factor for development of ACR within the first year of kidney transplantation and 1,25-dihydroxyvitamin D3 supplementation may help reduce the occurrence of ACR in the vitamin D-deficient group.
BACKGROUND:Vitamin D, in addition to its established role in bone metabolism, may regulate the immune system and affect the outcome of allografts. METHODS: We identified 351 kidney allograft recipients who had serum levels of 25-hydroxyvitamin D (25[OH]D) measured within the first 30 days of transplantation. We evaluated the relationship between the circulating levels of 25(OH)D and acute cellular rejection (ACR), cytomegalovirus (CMV) disease, BK virus nephropathy, and kidney graft function. RESULTS:Vitamin D deficiency (circulating levels of 25[OH]D ≤20 ng/mL, defined using The Endocrine Society Clinical Practice 2011 Guideline) was observed in 216 (61.5%) of 351 kidney graft recipients. Vitamin D deficiency was more frequent in female recipients (P=0.007, Fisher exact test) and African American recipients (P<0.001) and was less frequent in preemptive kidney graft recipients (P=0.002). Biopsy-confirmed ACR was more frequent in the vitamin D-deficient group than in the sufficient group (10.2% vs. 3.7%, P=0.04). By multivariable Cox regression analysis, vitamin D deficiency was an independent risk factor for ACR (hazard ratio=3.3, P=0.02). Vitamin D deficiency was not associated with CMV disease, BK virus nephropathy, or kidney allograft function at 1 year. 1,25-Dihydroxyvitamin D3 supplementation initiated within the first 90 days of transplantation was associated with a lesser incidence of ACR compared to no treatment with 1,25-dihydroxyvitamin D3 (5.1% vs. 13.0%, P=0.099). CONCLUSIONS:Vitamin D deficiency is an independent risk factor for development of ACR within the first year of kidney transplantation and 1,25-dihydroxyvitamin D3 supplementation may help reduce the occurrence of ACR in the vitamin D-deficient group.
Authors: Jaquelyn K O'Herrin; Debra A Hullett; Dennis M Heisey; Hans W Sollinger; Bryan N Becker Journal: Am J Nephrol Date: 2002 Sep-Dec Impact factor: 3.754
Authors: Debra A Hullett; Paul F Laeseke; Gretchen Malin; Regina Nessel; Hans W Sollinger; Bryan N Becker Journal: Transpl Int Date: 2005-10 Impact factor: 3.782
Authors: C A Redaelli; M Wagner; Y H Tien; L Mazzucchelli; P F Stahel; M K Schilling; J F Dufour Journal: Hepatology Date: 2001-11 Impact factor: 17.425
Authors: Antoine Bouquegneau; Syrazah Salam; Pierre Delanaye; Richard Eastell; Arif Khwaja Journal: Clin J Am Soc Nephrol Date: 2016-02-15 Impact factor: 8.237
Authors: Lily Li; Marvin Lin; Maria Krassilnikova; Katya Ostrow; Amanda Bader; Brian Radbill; Jaime Uribarri; Joji Tokita; Staci Leisman; Vijay Lapsia; Randy A Albrecht; Adolfo García-Sastre; Andrea D Branch; Peter S Heeger; Anita Mehrotra Journal: PLoS One Date: 2014-10-08 Impact factor: 3.240
Authors: Franz J J Rieder; Charlotte Gröschel; Marie-Theres Kastner; Karin Kosulin; Johannes Laengle; Rene Zadnikar; Rodrig Marculescu; Martina Schneider; Thomas Lion; Michael Bergmann; Enikö Kallay; Christoph Steininger Journal: J Steroid Biochem Mol Biol Date: 2016-08-09 Impact factor: 4.292